Mereo BioPharma Group plc Share Price & Technical Analysis
MREO · $0.28 (+3.70%)
Healthcare / Biotechnology
$0.28
+3.70%
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disea…
Price chart
Seasonality
May has 1 positive and 3 negative years (last 5 years shown)
0% return in May, -9% avg return in past 3 year May month.
0% return in 2026, 32% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 0% | 0% | 0% | 0% | – | – | – | – | – | – | – | 0% |
| 25 | -14% | -17% | -8% | 18% | -15% | 23% | -37% | 0% | 24% | -10% | 0% | -79% | -116% |
| 24 | 65% | 0% | -13% | -9% | 13% | 3% | 17% | 15% | -13% | 0% | -14% | -3% | 61% |
| 23 | 13% | 0% | -22% | 86% | -23% | 30% | 0% | 8% | -7% | 54% | 5% | 10% | 152% |
| 22 | -24% | -8% | -8% | -45% | -17% | 120% | 0% | 0% | -18% | 11% | -20% | 0% | -9% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2. It also develops Leflutrozole, an oral aromatase inhibitor, which is in Phase 2 trials for use in the treatment of hypogonadotropic hypogonadism; Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Etigilimab, an IgG1 monoclonal antibody which binds to the human TIGIT receptor on immune cells for the Treatment of advanced solid tumors; and Acumapimod, a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, United Kingdom.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$39.81M
P/E ratio
—
52W high
$3.05
52W low
$0.20
Volume
19,05,063
Beta
0.19
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Mereo BioPharma Group plc share price today?
- Mereo BioPharma Group plc (MREO) last traded around $0.28 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does MREO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for MREO. Download the app for real-time alerts.
- How can I analyze Mereo BioPharma Group plc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.